Study identification

EU PAS number

EUPAS1000000551

Study ID

1000000551

Official title and acronym

Comparative Effectiveness of Ticagrelor vs. Prasugrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

DARWIN EU® study

No

Study countries

Australia
Korea, Republic of
United States

Study description

This study aims to compare ticagrelor and prasugrel, P2Y12 antiplatelet agents commonly used in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).
Given ongoing uncertainty from prior trials, mixed guideline recommendations, and the limitations of previous observational research, additional rigorous real-world evidence is needed to clarify optimal treatment strategies for ACS.
By conducting a direct, head-to-head comparison, this research will provide valuable insights into their comparative effectiveness and safety.

Study status

Ongoing
Research institutions and networks

Institutions

UMass Chan Medical School
UT Southwestern
University of New Mexico
VUMC
Penn State Health
UNSW Sydney
Health Partners

Networks

Contact details

Chang Hoon Han 0000-0002-8092-5884

Primary lead investigator
ORCID number:
0000-0002-8092-5884
Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Actual:

Date of final study report

Planned:
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable